Information about upcoming Novartis FTY720 clinical trials
Submitted by hollie on Tue, 2007-06-05 07:08.
It looks like Novartis is getting ready to start two Phase 3 trials of its new oral MS drug, FTY720 (aka fingolimod). One is a 24-month placebo-controlled study, and the other is a 12-month comparison with Avonex. The company has put up an informational web site with brief descriptions of the trials, an eligibility questionnaire, and contact details for the enrolling sites. You can also go to clinicaltrials.gov for additional information on these trials.